Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Eribulin|DRUG: Trastuzumab
Sponsor: SCRI Development Innovations, LLC
Collaborators: Eisai Inc.